Skip to main content
PMC home page
Environmental Health and Preventive Medicine logoLink to Environmental Health and Preventive Medicine
. 2007 Jul;12(4):153–160. doi: 10.1007/BF02897984

Keynote lecture in the 13th Japanese Society of Immunotoxicology (JSIT 2006)

—Pathophysiological Development and Immunotoxicology: what we have found from research related to silica and silicate such as asbestos—

Takemi Otsuki 1,✉, Yoshie Miura 1, Megumi Maeda 1, Hiroaki Hayashi 1, Shuko Murakami 1, Maolong Dong 1,3, Yasumitsu Nishimura 1
PMCID: PMC2723295  PMID: 21432058

Abstract

Silica and silicates may disturb immune functions such as autoimmunity and tumor immunity, because people who are exposed to the materials sometimes develop autoimmune and malignant diseases, respectively. Although silica-induced disorders of autoimmunity have been explained as adjuvant-type effects of silica, more precise analyses are needed and should reflect the recent progress in immunomolecular findings. A brief summary of our investigations related to the immunological effects of silica/asbestos is presented. Recent advances in immunomolecular studies led to detailed analyses of the immunological effects of asbestos and silica. Both affect immuno-competent cells and these effects may be associated with the pathophysiological development of complications in silicosis and asbestos-exposed patients such as the occurrence of autoimmune disorders and malignant tumors, respectively. In addition, immunological analyses may lead to the development of new clinical tools for the modification of the pathophysiological aspects of diseases such as the regulation of autoimmunity or tumor immunity using cell-mediated therapies, various cytokines, and molecule-targeting therapies. In particular, as the incidence of asbestos-related malignancies is increasing and such malignancies have been a medical and social problem since the summer in 2005 in Japan, efforts should be focused on developing a cure for these diseases to eliminate the nation wide anxiety about these malignancies.

Key words: silica, asbestos, immunology Fas, regulatory T cell, apoptosis

References

  • (1).Bartunkova J, Tesar V, Sediva A. Diagnostic and pathogenetic role of antineutrophil cytoplasmic autoantibodies. Clin Immunol. 2003; 106: 73–82. [DOI] [PubMed]
  • (2).Steenland K, Goldsmith DF. Silica exposure and autoimmune diseases. Am J Ind Med. 1995; 28: 603–608. [DOI] [PubMed]
  • (3).Uber CL, McReynolds RA. Immunotoxicology of silica. Crit Rev Toxicol. 1982; 10: 303–319. [DOI] [PubMed]
  • (4).Caplan A. Rheumatoid pneumoconiosis syndrome. Med Lav. 1965; 56: 494–499. [PubMed]
  • (5).Caplan A. Contribution to discussion on rheumatoid pneumoconiosis. Grundfragen Silikoseforsch. 1963; 6: 345–349. [PubMed]
  • (6).Lamvik J. Rheumatoid pneumoconiosis. A case of Caplan’s syndrome in a chalk-mine worker. Acta Pathol Microbiol Scand. 1963; 57: 169–174. [PubMed]
  • (7).Mayes MD. Epidemiologic studies of environmental agents and systemic autoimmune diseases. Environ Health Perspect. 1999; 107S5: 743–748. [DOI] [PMC free article] [PubMed]
  • (8).Brown SL, Langone JJ, Brinton LA. Silicone breast implants and autoimmune disease. J Am Med Womens Assoc. 1998; 53: 21–24, 40. [PubMed]
  • (9).Reyes H, Ojo-Amaize EA, Peter JB. Silicates, silicones and autoimmunity. Isr J Med Sci. 1997; 33: 239–242. [PubMed]
  • (10).Jenkins ME, Friedman HI, von Recum AF. Breast implants: facts, controversy, and speculations for future research. J Invest Surg. 1996; 9: 1–12. [DOI] [PubMed]
  • (11).Gilson JC. Health hazards of asbestos. Recent studies on its biological effects. Trans Soc Occup Med. 1966; 16: 62–74. [DOI] [PubMed]
  • (12).Rom WN, Palmer PE. The spectrum of asbestos-related diseases. West J Med. 1974; 121: 10–21. [PMC free article] [PubMed]
  • (13).Dodson RF, Hammar SP. Asbestos: Risk Assessment, Epidemiology, and Health Effects. Boca Raton, FL: CRC Press Taylor & Francis Group; 2006.
  • (14).Roccli VL, Oury TD, Sporn TA. Asebstos-associated Diseases. 2nd ed. New York, U.S.A.: Springer; 2004.
  • (15).Nagata S. Fas and Fas ligand: a death factor and its receptor. Adv Immunol. 1994; 57: 129–144. [DOI] [PubMed]
  • (16).Nagata S, Suda T. Fas and Fas ligand: lpr and gld mutations. Immunol Today. 1995; 16: 39–43. [DOI] [PubMed]
  • (17).Ferguson TA, Griffith TS. A vision of cell death. Fas ligand and immune privilege 10 years later. Immunol Rev. 2006; 213: 228–238. [DOI] [PubMed]
  • (18).Kim KS. Multifunctional role of Fas-associated death domain protein in apoptosis. J Biochem Mol Biol. 2002; 35: 1–6. [DOI] [PubMed]
  • (19).Peng SL. Fas (CD95)-related apoptosis and rheumatoid arthritis. Rheumatology (Oxford). 2006; 45: 26–30. [DOI] [PubMed]
  • (20).Pinkoski MJ, Green DR. Fas ligand, death gene. Cell Death Differ. 1996; 6: 1174–1181. [DOI] [PubMed]
  • (21).Owen-Schaub L, Chan H, Cusack JC, Roth J, Hill LL. Fas and Fas ligand interactions in malignant disease. Int J Oncol. 2000; 17: 5–12. [PubMed]
  • (22).Bettinardi A, Brugnoni D, Quiros-Roldan E, Malagoli A, La Grutta S, Correra A, et al. Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: a molecular and immunological analysis. Blood. 1997; 89: 902–909. [PubMed]
  • (23).Hasunuma T, Kayagaki N, Asahara H, Motokawa S, Kobata T, Yagita H, et al. Accumulation of soluble Fas in inflamed joints of patients with rheumatoid arthritis. Arthritis Rheum. 1997; 40: 80–86. [DOI] [PubMed]
  • (24).Tokano Y, Miyake S, Kayagaki N, Nozawa K, Morimoto S, Azuma M, et al. Soluble Fas molecule in the serum of patients with systemic lupus erythematosus. J Clin Immunol. 1996; 16: 261–265. [DOI] [PubMed]
  • (25).Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science. 1994; 263: 1759–1762. [DOI] [PubMed]
  • (26).Tomokuni A, Aikoh T, Matsuki T, Isozaki Y, Otsuki T, Kita S, et al. Elevated soluble Fas/APO-1 (CD95) levels in silicosis patients without clinical symptoms of autoimmune diseases or malignant tumors. Clin Exp Immunol 1997; 110: 303–309. [DOI] [PMC free article] [PubMed]
  • (27).Tomokuni A, Otsuki T, Isozaki Y, Kita S, Ueki H, Kusaka M, et al. Serum levels of soluble Fas ligand in patients with silicosis. Clin Exp Immunol. 1999; 118: 441–444. [DOI] [PMC free article] [PubMed]
  • (28).Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F, et al. Fas ligand in human serum. Nat Med. 1996; 2: 317–322. [DOI] [PubMed]
  • (29).Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, Inoue S, et al. Metalloproteinase-mediated release of human Fas ligand. J Exp Med. 1995; 182: 1777–1783. [DOI] [PMC free article] [PubMed]
  • (30).Otsuki T, Miura Y, Nishimura Y, Hyodoh F, Takata A, Kusaka M, et al. Alterations of Fas and Fas-related molecules in patients with silicosis. Exp Biol Med (Maywood). 2006; 231: 522–533. [DOI] [PubMed]
  • (31).Otsuki T, Sakaguchi H, Tomokuni A, Aikoh T, Matsuki T, Kawakami Y, et al. Soluble Fas mRNA is dominantly expressed in cases with silicosis. Immunology. 1998; 94: 258–262. [DOI] [PMC free article] [PubMed]
  • (32).Otsuki T, Tomokuni A, Sakaguchi H, Aikoh T, Matsuki T, Isozaki Y, et al. Over-expression of the decoy receptor 3 (DcR3) gene in peripheral blood mononuclear cells (PBMC) derived from silicosis patients. Clin Exp Immunol. 2000; 119: 323–327. [DOI] [PMC free article] [PubMed]
  • (33).Otsuki T, Tomokuni A, Sakaguchi H, Hyodoh F, Kusaka M, Ueki A. Reduced expression of the inhibitory genes for Fasmediated apoptosis in silicosis patients. J Occup Health. 2000; 42: 163–168. [DOI]
  • (34).Guo Z-Q, Otsuki T, Shimizu T, Tachiyama S, Sakaguchi H, Isozaki Y, et al. Reduced expression of survivin gene in PBMC from silicosis patients. Kwasaki Med J. 2001; 27: 75–81.
  • (35).Bai C, Connolly B, Metzker ML, Hilliard CA, Liu X, Sandig V, et al. Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster. Proc Natl Acad Sci U S A. 2000; 97: 1230–1235. [DOI] [PMC free article] [PubMed]
  • (36).Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature. 1998; 396: 699–703. [DOI] [PubMed]
  • (37).Otsuki T, Sakaguchi H, Tomokuni A, Aikoh T, Matsuki T, Isozaki Y, et al. Detection of alternatively spliced variant messages of Fas gene and mutational screening of Fas and Fas ligand coding regions in peripheral blood mononuclear cells derived from silicosis patients. Immunol Lett. 2000; 72: 137–143. [DOI] [PubMed]
  • (38).Takata-Tomokuni A, Ueki A, Shiwa M, Isozaki Y, Hatayama T, Katsuyama H, et al. Detection, epitope-mapping, and function of anti-Fas autoantibody in patients with silicosis. Immunology. 2005; 116: 21–29. [DOI] [PMC free article] [PubMed]
  • (39).Ueki A, Isozaki Y, Tomokuni A, Hatayama T, Ueki H, Kusaka M, et al. Intramolecular epitope spreading among anti-caspase-8 autoantibodies in patients with silicosis, systemic sclerosis and systemic lupus erythematosus, as well as in healthy individuals. Clin Exp Immunol. 2002; 129: 556–561. [DOI] [PMC free article] [PubMed]
  • (40).Ueki A, Isozaki Y, Kusaka M. Anti-caspase-8 autoantibody response in silicosis patients is associated with HLA-DRB1, DQB1 and DPB1 alleles J Occup Health. 2005; 47: 61–67. [DOI] [PubMed]
  • (41).Wu P, Hyodoh F, Hatayama T, Sakaguchi H, Hatada S, Miura Y, et al. Induction of CD69 antigen expression in peripheral blood mononuclear cells on exposure to silica, but not by asbestos/chrysotile-A. Immunol Lett. 2005; 98: 145–152. [DOI] [PubMed]
  • (42).Wu P, Miura Y, Hyodoh F, Nishimura Y, Hatayama T, Hatada S, et al. Reduced function of CD4+25+ regulatory T cell fraction in silicosis patients. Int J Immunopathol Pharmacol. 2006; 19: 357–368. [DOI] [PubMed]
  • (43).Otsuki T, Takata A, Hyodoh F, Ueki A, Matsuo Y, Kusaka M. Dysregulation of Fas-mediated apoptotic pathway in silicosis patients. Rec Res Develop Immunol. 2002; 4: 703–713.
  • (44).Otsuki T, Takata A, Hyodoh F, Ueki A. Review of regulation for the Fas-mediated apoptotic pathway in silicosis patients. Kawasaki Med J. 2003; 29: 33–43.
  • (45).Takahashi T, Sakaguchi S. The role of regulatory T cells in controlling immunologic self-tolerance. Int Rev Cytol. 2003; 225: 1–32. [DOI] [PubMed]
  • (46).Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells. their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev. 2001; 182: 18–32. [DOI] [PubMed]
  • (47).Sakaguchi S. Animal models of autoimmunity and their relevance to human diseases. Curr Opin Immunol. 2000; 12: 684–690. [DOI] [PubMed]
  • (48).Sakaguchi S, Toda M, Asano M, Itoh M, Morse SS, Sakaguchi N. T cell-mediated maintenance of natural self-tolerance: its breakdown as a possible cause of various autoimmune diseases. J Autoimmun. 1996; 9: 211–220. [DOI] [PubMed]
  • (49).Venet F, Pachot A, Debard AL, Bohe J, Bienvenu J, Lepape A, et al. Human CD4+CD25+ regulatory T lymphocytes inhibit lipopolysaccharide-induced monocyte survival through a Fas/Fas ligand-dependent mechanism. J Immunol. 2006; 177: 6540–6547. [DOI] [PubMed]
  • (50).Fritzsching B, Oberle N, Pauly E, Geffers R, Buer J, Poschl J, et al., Naive regulatory T cells: a novel subpopulation defined by resistance toward CD95L-mediated cell death. Blood. 2006; 108: 3371–3378. [DOI] [PubMed]
  • (51).Yuan Z, Taatjes DJ, Mossman BT, Heintz NH. The duration of nuclear extracellular signal-regulated kinase 1 and 2 signaling during cell cycle reentry distinguishes proliferation from apoptosis in response to asbestos. Cancer Res. 2004; 64: 6530–6536. [DOI] [PubMed]
  • (52).Shukla A, Stern M, Lounsbury KM, Flanders T, Mossman BT. Asbestos-induced apoptosis is protein kinase C delta-dependent. Am J Respir Cell Mol Biol. 2003; 29: 198–205. [DOI] [PubMed]
  • (53).Cummins AB, Palmer C, Mossman BT, Taatjes DJ. Persistent localization of activated extracellular signal-regulated kinases (ERK1/2) is epithelial cell-specific in an inhalation model of asbestosis. Am J Pathol. 2003; 162: 713–720. [DOI] [PMC free article] [PubMed]
  • (54).Puhakka A, Ollikainen T, Soini Y, Kahlos K, Saily M, Koistinen P, et al. Modulation of DNA single-strand breaks by intracellular glutathione in human lung cells exposed to asbestos fibers. Mutat Res. 2002; 514: 7–17. [DOI] [PubMed]
  • (55).Ollikainen T, Puhakka A, Kahlos K, Linnainmaa K, Kinnula VL. Modulation of cell and DNA damage by poly(ADP)ribose polymerase in lung cells exposed to H2O2 or asbestos fibres. Mutat Res. 2000; 470: 77–84. [DOI] [PubMed]
  • (56).Adamson IY. Early mesothelial cell proliferation after asbestos exposure:in vivo andin vitro studies. Environ Health Perspect. 1997; 105S5: 1205–1208. [DOI] [PMC free article] [PubMed]
  • (57).BeruBe KA, Quinlan TR, Moulton G, Hemenway D, O’Shaughnessy P, Vacek P, et al. Comparative proliferative and histopathologic changes in rat lungs after inhalation of chrysotile or crocidolite asbestos. Toxicol Appl Pharmacol. 1996; 137: 67–74. [DOI] [PubMed]
  • (58).Kamp DW, Graceffa P, Pryor WA, Weitzman SA. The role of free radicals in asbestos-induced diseases. Free Radic Biol Med. 1992; 12: 293–315. [DOI] [PubMed]
  • (59).Rom WN, Travis WD, Brody AR. Cellular and molecular basis of the asbestos-related diseases. Am Rev Respir Dis. 1991; 143: 408–422. [DOI] [PubMed]
  • (60).Haura EB, Zheng Z, Song L, Cantor A, Bepler G. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survivalin vivo in non-small cell lung cancer. Clin Cancer Res. 2005; 11: 8288–8294. [DOI] [PubMed]
  • (61).Song L, Turkson J, Karras JG, Jove R, Haura EB. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene. 2003; 22: 4150–4165. [DOI] [PubMed]
  • (62).Vega MI, Huerta-Yepez S, Jazirehi AR, Garban H, Bonavida B. Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis. Oncogene. 2005; 24: 8114–8127. [DOI] [PubMed]
  • (63).Vega MI, Huerta-Yepaz S, Garban H, Jazirehi A, Emmanouilides C, Bonavida B. Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance. Oncogene. 2004; 23: 3530–3540. [DOI] [PubMed]
  • (64).Whitson BA, Kratzke RA. Molecular pathways in malignant pleural mesothelioma. Cancer Lett. 2006; 239: 183–189. [DOI] [PubMed]
  • (65).Carbone M, Kratzke RA, Testa JR. The pathogenesis of mesothelioma. Semin Oncol. 2002; 29: 2–17. [DOI] [PubMed]
  • (66).Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet. 2005; 366: 397–408. [DOI] [PubMed]
  • (67).Aikoh T, Tomokuni A, Matsuki T, Hyodoh F, Ueki H, Otsuki T, et al. Activation-induced cell death in human peripheral blood lymhpocytes after stimulation with silicatein vitro. Int J Oncol. 1998; 12: 1355–1359. [DOI] [PubMed]
  • (68).Ma Z, Otsuki T, Tomokuni A, Aikoh T, Matsuki T, Sakaguchi H, et al. Man-made mineral fibers induce apoptosis of human peripheral blood mononuclear cells similar to chrysotile B. Int J Mol Med. 1999; 4: 633–637. [DOI] [PubMed]
  • (69).Hyodoh F, Takata-Tomokuni A, Miura Y, Sakaguchi H, Hatayama T, Hatada S, et al. Inhibitory effects of anti-oxidants on apoptosis of a human polyclonal T cell line, MT-2, induced by an asbestos, chrysotile-A. Scand J Immunol. 2005; 61: 442–448. [DOI] [PubMed]
  • (70).Miura Y, Nishimura Y, Katsuyama H, Maeda M, Hayashi H, Dong M, et al. Involvement of IL-10 and Bcl-2 in resistance against an asbestos-induced apoptosis of T cells. Apoptosis. 2006; 11: 1825–1835. [DOI] [PubMed]
  • (71).Nishimura Y, Miura Y, Maeda M, Hayashi H, Dong M, Katsuyama H, et al. Expression of the T cell receptor Vβ repertoire in a human T cell resistant to asbestos-induced apoptosis and peripheral blood T cells from patients with silica and asbestos-related diseases. Int J Immunopathol Pharmacol. 2006; 19: 795–805. [DOI] [PubMed]

Articles from Environmental Health and Preventive Medicine are provided here courtesy of The Japanese Society for Hygiene

RESOURCES